ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China
· Delayed Price · Currency is CNY 42.61
-0.14 (-0.33%)
Mar 9, 2026, 4:00 PM EDT
ChengDa Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Operating Revenue | 372.17 | 330.85 | 413.28 | 411.34 | 415.59 | 372.96 | Upgrade
|
| Other Revenue | 2.28 | 2.28 | 1.03 | 0.12 | 0.14 | 0.07 | Upgrade
|
| Revenue | 374.46 | 333.13 | 414.3 | 411.46 | 415.73 | 373.04 | Upgrade
|
| Revenue Growth (YoY) | -5.87% | -19.59% | 0.69% | -1.03% | 11.44% | 26.90% | Upgrade
|
| Cost of Revenue | 225.4 | 207.33 | 238.93 | 228.55 | 215.7 | 193.47 | Upgrade
|
| Gross Profit | 149.06 | 125.8 | 175.37 | 182.92 | 200.02 | 179.57 | Upgrade
|
| Selling, General & Admin | 119.04 | 99.58 | 85.59 | 88.01 | 66.83 | 56.31 | Upgrade
|
| Research & Development | 94.21 | 93.71 | 27.46 | 19.44 | 17.22 | 18.98 | Upgrade
|
| Other Operating Expenses | 6.78 | 4.28 | 3.57 | 4.15 | 2.47 | 3.41 | Upgrade
|
| Operating Expenses | 224.81 | 195.86 | 117.69 | 112.65 | 87.95 | 77.65 | Upgrade
|
| Operating Income | -75.75 | -70.06 | 57.68 | 70.27 | 112.08 | 101.92 | Upgrade
|
| Interest Expense | -0.3 | -0.3 | - | -0.2 | -1.4 | -2.68 | Upgrade
|
| Interest & Investment Income | 17.36 | 32.81 | 48.19 | 40.25 | 0.26 | 0.47 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.4 | 2.4 | 1.45 | 4.7 | -1.51 | -3.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.43 | 2.91 | -5.06 | -0.16 | -0.1 | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | -53.86 | -32.24 | 102.26 | 114.87 | 109.33 | 96.45 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.57 | 1.6 | - | 0.39 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | 0.2 | 0 | -0.53 | -0.02 | 41.86 | Upgrade
|
| Asset Writedown | -3.48 | -2.53 | -3.51 | -3.43 | -2.62 | -1.85 | Upgrade
|
| Other Unusual Items | 6.23 | 5.78 | 5.5 | 8.81 | 8.6 | 3.06 | Upgrade
|
| Pretax Income | -51.65 | -27.18 | 104.25 | 120.11 | 115.29 | 139.51 | Upgrade
|
| Income Tax Expense | -0.26 | 0.46 | 13.15 | 13.63 | 15.01 | 19.91 | Upgrade
|
| Earnings From Continuing Operations | -51.38 | -27.64 | 91.1 | 106.48 | 100.27 | 119.61 | Upgrade
|
| Minority Interest in Earnings | -0.34 | -0.46 | -0.12 | 0.01 | 0.16 | 1.57 | Upgrade
|
| Net Income | -51.72 | -28.1 | 90.98 | 106.48 | 100.44 | 121.17 | Upgrade
|
| Net Income to Common | -51.72 | -28.1 | 90.98 | 106.48 | 100.44 | 121.17 | Upgrade
|
| Net Income Growth | - | - | -14.56% | 6.02% | -17.11% | 123.47% | Upgrade
|
| Shares Outstanding (Basic) | 151 | 152 | 155 | 151 | 116 | 116 | Upgrade
|
| Shares Outstanding (Diluted) | 151 | 152 | 155 | 151 | 116 | 116 | Upgrade
|
| Shares Change (YoY) | -0.87% | -1.75% | 2.12% | 30.56% | -0.00% | 9.67% | Upgrade
|
| EPS (Basic) | -0.34 | -0.18 | 0.59 | 0.70 | 0.87 | 1.04 | Upgrade
|
| EPS (Diluted) | -0.34 | -0.18 | 0.59 | 0.70 | 0.87 | 1.04 | Upgrade
|
| EPS Growth | - | - | -16.33% | -18.80% | -17.11% | 103.77% | Upgrade
|
| Free Cash Flow | -174.51 | -257.72 | -32.6 | -158.03 | -55.56 | 65.16 | Upgrade
|
| Free Cash Flow Per Share | -1.15 | -1.70 | -0.21 | -1.04 | -0.48 | 0.56 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.188 | 0.281 | - | Upgrade
|
| Dividend Growth | - | - | 6.67% | -33.34% | - | - | Upgrade
|
| Gross Margin | 39.81% | 37.76% | 42.33% | 44.45% | 48.11% | 48.14% | Upgrade
|
| Operating Margin | -20.23% | -21.03% | 13.92% | 17.08% | 26.96% | 27.32% | Upgrade
|
| Profit Margin | -13.81% | -8.44% | 21.96% | 25.88% | 24.16% | 32.48% | Upgrade
|
| Free Cash Flow Margin | -46.60% | -77.36% | -7.87% | -38.41% | -13.36% | 17.47% | Upgrade
|
| EBITDA | -24.22 | -23.22 | 98.28 | 105.58 | 142.56 | 128.26 | Upgrade
|
| EBITDA Margin | -6.47% | -6.97% | 23.72% | 25.66% | 34.29% | 34.38% | Upgrade
|
| D&A For EBITDA | 51.53 | 46.85 | 40.6 | 35.32 | 30.49 | 26.34 | Upgrade
|
| EBIT | -75.75 | -70.06 | 57.68 | 70.27 | 112.08 | 101.92 | Upgrade
|
| EBIT Margin | -20.23% | -21.03% | 13.92% | 17.08% | 26.96% | 27.32% | Upgrade
|
| Effective Tax Rate | - | - | 12.61% | 11.35% | 13.02% | 14.27% | Upgrade
|
| Revenue as Reported | 374.46 | 333.13 | 414.3 | 411.46 | 415.73 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.